Short Communication : Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial
Antiretroviral treatment simplification strategies based on monotherapy with darunavir/ritonavir (DRV/r) or lopinavir/ritonavir (LPV/r) have not been directly compared in clinical trials. We evaluated the 48-week efficacy and safety of DRV/r versus LPV/r monotherapy as a treatment simplification strategy in a multicenter, randomized open-label study. Maintenance of viral suppression in cerebrospinal fluid (CSF) and semen was also explored. An intention to treat efficacy analysis was performed considering missing equals to failure (ITT:M = F). Virological failure (VF) was defined as a confirmed increase in plasma HIV-1 RNA >50 copies/mL. A total of 75 patients were enrolled: 40 were allocated to DRVr and 33 to LPVr. In the ITT: M = F analysis, 77.5% of patients on DRV/r and 66.6% of patients on LPV/r maintained HIV-1 RNA <50 copies/mL at week 48 (p = .302, treatment difference 10.8% [95% CI,-12.6 to 34.2]). In the DRV/r arm, no patients developed VF and 15.0% discontinued treatment due to adverse events. In the LPV/r arm, 2 (6.1%) patients developed VF and 18.2% discontinued monotherapy due to adverse events. Gastrointestinal disturbances were experienced by 18.2% and 2.5% of patients in the LPV/r and DRV/r arms, respectively (p = .019). Two patients had detectable HIV-1 RNA ≥50 copies/mL in CSF or semen. Monotherapy with LPV/r or DRV/r seems to be virologically effective in selected HIV-1-infected patients with sustained viral suppression. Differences between both regimens seem driven mainly by the better tolerability profile of DRV/r.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2016 |
---|---|
Erschienen: |
2016 |
Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
---|---|
Enthalten in: |
AIDS research and human retroviruses - 32(2016), 5 vom: 17. Mai, Seite 452-5 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Santos, José R [VerfasserIn] |
---|
Links: |
---|
Themen: |
2494G1JF75 |
---|
Anmerkungen: |
Date Completed 09.01.2017 Date Revised 10.01.2017 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1089/AID.2015.0248 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM25657507X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM25657507X | ||
003 | DE-627 | ||
005 | 20231224180939.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2016 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1089/AID.2015.0248 |2 doi | |
028 | 5 | 2 | |a pubmed24n0855.xml |
035 | |a (DE-627)NLM25657507X | ||
035 | |a (NLM)26781004 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Santos, José R |e verfasserin |4 aut | |
245 | 1 | 0 | |a Short Communication |b Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial |
264 | 1 | |c 2016 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 09.01.2017 | ||
500 | |a Date Revised 10.01.2017 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Antiretroviral treatment simplification strategies based on monotherapy with darunavir/ritonavir (DRV/r) or lopinavir/ritonavir (LPV/r) have not been directly compared in clinical trials. We evaluated the 48-week efficacy and safety of DRV/r versus LPV/r monotherapy as a treatment simplification strategy in a multicenter, randomized open-label study. Maintenance of viral suppression in cerebrospinal fluid (CSF) and semen was also explored. An intention to treat efficacy analysis was performed considering missing equals to failure (ITT:M = F). Virological failure (VF) was defined as a confirmed increase in plasma HIV-1 RNA >50 copies/mL. A total of 75 patients were enrolled: 40 were allocated to DRVr and 33 to LPVr. In the ITT: M = F analysis, 77.5% of patients on DRV/r and 66.6% of patients on LPV/r maintained HIV-1 RNA <50 copies/mL at week 48 (p = .302, treatment difference 10.8% [95% CI,-12.6 to 34.2]). In the DRV/r arm, no patients developed VF and 15.0% discontinued treatment due to adverse events. In the LPV/r arm, 2 (6.1%) patients developed VF and 18.2% discontinued monotherapy due to adverse events. Gastrointestinal disturbances were experienced by 18.2% and 2.5% of patients in the LPV/r and DRV/r arms, respectively (p = .019). Two patients had detectable HIV-1 RNA ≥50 copies/mL in CSF or semen. Monotherapy with LPV/r or DRV/r seems to be virologically effective in selected HIV-1-infected patients with sustained viral suppression. Differences between both regimens seem driven mainly by the better tolerability profile of DRV/r | ||
650 | 4 | |a Comparative Study | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a HIV Protease Inhibitors |2 NLM | |
650 | 7 | |a Lopinavir |2 NLM | |
650 | 7 | |a 2494G1JF75 |2 NLM | |
650 | 7 | |a Ritonavir |2 NLM | |
650 | 7 | |a O3J8G9O825 |2 NLM | |
650 | 7 | |a Darunavir |2 NLM | |
650 | 7 | |a YO603Y8113 |2 NLM | |
700 | 1 | |a Llibre, Josep M |e verfasserin |4 aut | |
700 | 1 | |a Bravo, Isabel |e verfasserin |4 aut | |
700 | 1 | |a García-Rosado, Dácil |e verfasserin |4 aut | |
700 | 1 | |a Cañadas, Mari Paz |e verfasserin |4 aut | |
700 | 1 | |a Pérez-Álvarez, Nuria |e verfasserin |4 aut | |
700 | 1 | |a Paredes, Roger |e verfasserin |4 aut | |
700 | 1 | |a Clotet, Bonaventura |e verfasserin |4 aut | |
700 | 1 | |a Moltó, José |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t AIDS research and human retroviruses |d 1990 |g 32(2016), 5 vom: 17. Mai, Seite 452-5 |w (DE-627)NLM012611727 |x 1931-8405 |7 nnns |
773 | 1 | 8 | |g volume:32 |g year:2016 |g number:5 |g day:17 |g month:05 |g pages:452-5 |
856 | 4 | 0 | |u http://dx.doi.org/10.1089/AID.2015.0248 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 32 |j 2016 |e 5 |b 17 |c 05 |h 452-5 |